Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

Background This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2018-01, Vol.23 (1), p.7-15
Hauptverfasser:	Moriwaki, Toshikazu, Fukuoka, Shota, Taniguchi, Hiroya, Takashima, Atsuo, Kumekawa, Yusuke, Kajiwara, Takeshi, Yamazaki, Kentaro, Esaki, Taito, Makiyama, Chinatsu, Denda, Tadamichi, Satake, Hironaga, Suto, Takeshi, Sugimoto, Naotoshi, Enomoto, Masanobu, Ishikawa, Toshiaki, Kashiwada, Tomomi, Sugiyama, Masahiko, Komatsu, Yoshito, Okuyama, Hiroyuki, Baba, Eishi, Sakai, Daisuke, Watanabe, Tomoki, Tamura, Takao, Yamashita, Kimihiro, Gosho, Masahiko, Shimada, Yasuhiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Colorectal cancer Gastrointestinal Cancer Propensity score Regorafenib TAS‐102 Trifluridine/tipiracil
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!